ライフサイエンスコーパス: ADME

1 ADME profiling of 14j suggested a long half-life in both

2 ADME SARfari is a freely available web resource that ena

3 ADME studies demonstrated for the most promising prodrug

4 with adequate brain penetration, acceptable ADME properties, no P-glycoprotein, and no hERG liabilit

5 valuation of the most potent compounds in an ADME panel showed that these compounds possess poor solu

6 On the basis of an ADME analysis, a new series of compounds, the arylazanyl

7 we compared the antimalarial activities and ADME profiles of the 1,2-dioxolane, 1,2,4-trioxane, and

8 lation between the antimalarial efficacy and ADME profiles in the rank order trioxolane > trioxane >

9 new ozonides with antimalarial efficacy and ADME profiles superior or equal to that of arterolane we

10 conceptual workflow to examine exposure and ADME properties in relation to an MIE.

11 The incorporation of exposure and ADME properties into the conceptual workflow eliminated

12 Here, we disclose SAR investigation and ADME/PK optimization leading to the identification of in

13 y optimization of the potency against Pf and ADME properties resulted in the identification of 12 as

14 The pharmacological and ADME profile of this corrector series hold promise for t

15 ion of pharmacological, physicochemical, and ADME properties of original lead 5a resulted in identifi

16 pound 51 exhibited good in vitro potency and ADME, which translated into a favorable in vivo pharmaco

17 r with its good physicochemical, safety, and ADME properties, led compound 28 to be selected as clini

18 Besides good potency, selectivity, and ADME properties, compound 48 displayed robust in vivo ac

19 demonstrating target engagement in vivo and ADME-PK properties that are suitable for further evaluat

20 teps, they remain the rate limiting steps as ADME (Absorption, Distribution, Metabolism, and Excretio

21 The new inhibitors showed beneficial ADME and pharmacokinetic profiles, and their binding mod

22 7 series, the trioxane isostere had the best ADME profile, but its overall antimalarial efficacy was

23 to have similar cytotoxic potency and better ADME characteristics relative to those of silvestrol.

24 ainst the alpha3 receptor subtype and better ADME profile.

25 Throughout this on-chip ADME process, the proposed device can be used as a relia

26 tes that were proposed earlier in a clinical ADME study.

27 Computational ADME (absorption, distribution, metabolism, and excretio

28 an ideal radioisotope with which to conduct ADME studies early in the drug development process.

29 icted CNS drug-like properties and desirable ADME/PK profile.

30 n, two candidates were selected for detailed ADME studies and in vitro and in vivo toxicological asse

31 mpound 2j showed a good balance of different ADME properties, high activity in cell-free assays, and

32 r cell proliferation assays and differential ADME properties when compared to other synthetic aurista

33 idic device was fabricated to mimic the drug ADME response test in vivo.

34 d to analogs with improved potency and early ADME properties.

35 ficiently incorporates the concept of early "ADME/Tox" considerations and provides a basic platform f

36 , distribution, metabolism, and elimination (ADME) and safety profiles.

37 , metabolism, distribution, and elimination (ADME) data analysis through the estimation of oral bioav

38 , distribution, metabolism, and elimination (ADME) of anthocyanin-rich foods are relatively unknown.

39 tion, distribution, metabolism, elimination (ADME), and physiologically based pharmacokinetics (PBPK)

40 m this series was found to exhibit excellent ADME properties and superior therapeutic potential compa

41 tive PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in v

42 on, distribution, metabolism, and excretion (ADME scheme) of administrated drug.

43 ion, distribution, metabolism and excretion (ADME) of bioactive compounds.

44 ion, distribution, metabolism and excretion (ADME) of metabolites and toxic organic solutes are orche

45 on, distribution, metabolism, and excretion (ADME) processes in fish can alter polychlorinated biphen

46 on, distribution, metabolism, and excretion (ADME) profiles of drug candidates, in particular intesti

47 on, distribution, metabolism, and excretion (ADME) properties of chemicals.

48 on, distribution, metabolism, and excretion (ADME) properties.

49 ion, distribution, metabolism and excretion (ADME) screening.

50 ion, distribution, metabolism and excretion (ADME) studies to late-stage human clinical trials--to el

51 on, distribution, metabolism, and excretion (ADME), low propensity for p-glycoprotein 1-mediated effl

52 ion, distribution, metabolism and excretion (ADME), provide guidance for physically coupling MPS, and

53 oup of industrial in silico and experimental ADME scientists, participating in the In Silico ADME Wor

54 These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapag

55 These data, coupled with a favorable ADME profile, support the potential of 20g to be an effe

56 rely diabetic db/db mice and has a favorable ADME profile.

57 their good in vitro potencies and favorable ADME properties.

58 hit compounds were potent and had favorable ADME properties but had poor microsomal and plasma stabi

59 s and cyclooxygenases, and possess favorable ADME properties.

60 ro GlyT-1 potency and selectivity, favorable ADME and in vitro pharmacological profiles, and suitable

61 ncy and selectivity in addition to favorable ADME properties.

62 blood assay and also shows a very favorable ADME profile leading to favorable predicted human pharma

63 To align improved potency with favorable ADME and in vitro safety, we applied prospective physico

64 nanomolar antiferroptotic activity, and good ADME properties suitable for application in in vivo dise

65 binding values in ranges predictive of good ADME profiles.

66 vitro and in vivo evaluations revealed good ADME properties qualifying 14c as a pharmacological tool

67 selective ITK inhibitor (GNE-9822) with good ADME properties in preclinical species.

68 rmine a baseline for a study group for human ADME and PBPK studies using (14)C as a tracer.

69 ((14)C) is an ideal tracer for in vivo human ADME (absorption, distribution, metabolism, elimination)

70 nked congeners with improved hysicochemical, ADME, and pharmacokinetic properties.

71 e to increase backbone diversity and improve ADME properties in cyclic peptide scaffolds.

72 to 10 (BMS-695735), which exhibits improved ADME properties, a low risk for drug-drug interactions,

73 ation and organ tissues that are involved in ADME testing.

74 ance (MDR) in tumors as well as to influence ADME properties of drug candidates.

75 ties for rapid and inexpensive assessment of ADME/Tox (absorption, distribution, metabolism, excretio

76 ified analogues with an excellent balance of ADME properties and potency; however, potential drug-dru

77 On the basis of ADME analysis, we describe herein a new series of tertia

78 an be recommended for use in optimization of ADME parameters of lead compounds in drug discovery.

79 al structures with IRAK4 and optimization of ADME properties to deliver clinical candidate PF-0665083

80 s were characterized in assays predictive of ADME/T and pharmacokinetic (PK) properties, allowing the

81 In preparation of ADME and PBPK studies, 12 healthy subjects were recruite

82 rmacokinetic (PK) data; protein sequences of ADME-related molecular targets for pre-clinical model sp

83 sulfonamides reported herein may also offer ADME advantages over known heteroaryl sulfonamide inhibi

84 Both LLE and LELP have significant impact on ADME and safety profiles; however, LELP outperforms LLE

85 Analyzing their impact on ADME and safety properties and binding thermodynamics, w

86 volved biochemical, cell-based, and tier-one ADME techniques.

87 In addition, 19d displayed an optimal ADME and safety profile (e.g., no thrombus formation).

88 ification of VEGFR-2 inhibitors with optimal ADME properties for an ocular indication provides opport

89 it identification, hit-to-lead optimization, ADME profile evaluation, and the structure-activity rela

90 highly selective ATM inhibitors with overall ADME properties suitable for oral administration.

91 metabolism, excretion, and pharmacokinetics (ADME-PK) properties of new chemical entities are an inte

92 ) exhibited excellent potency and in vivo PK/ADME properties.

93 Most preclinical leads exhibit poor ADME/PK properties and require optimizing to increase th

94 ed that low oral bioavailability due to poor ADME properties.

95 ization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the disc

96 The preclinical ADME properties of LY2562175 were consistent with enabli

97 Preliminary ADME studies indicated that some of the lead compounds a

98 d through qualitative screening and previous ADME studies.

99 drug candidates with potentially problematic ADME profiles.

100 eceptor (A2AAdoR) antagonist with reasonable ADME and pharmacokinetic properties.

101 Beyond potency and selectivity, ADME/PK and the toxicological profile of the compound pl

102 gy modeling methods, combined with in silico ADME calculations, were used to design analogues of comp

103 E scientists, participating in the In Silico ADME Working Group, a subgroup of the International Cons

104 on how to initiate and maintain an in silico ADME-PK infrastructure in an industrial setting.

105 e benefits, caveats, and impact of in silico ADME-PK should serve as a resource for medicinal chemist

106 bolites, making it possible to rapidly study ADME/PK in vivo without radiolabeling.

107 ly hits with moderate potency and suboptimal ADME properties led to the identification of several com

108 Subsequent ADME-PK optimization lead to 27, a predicted low clearan

109 n of a program lead compound with a suitable ADME/PK profile for therapeutic development.

110 though these compounds did not have suitable ADME properties to show in vivo efficacy in a mouse mode

111 oad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.

112 The ADME properties of 3 are similar to 1; viz., the O-aceta

113 ctural modifications designed to address the ADME issues, in particular permeability, were initially

114 these extended backbone elements impact the ADME properties of these hybrid molecules, especially th

115 active food constituent and investigated the ADME of [2-(14)C](-)-epicatechin (300 muCi, 60 mg) in hu

116 We investigated the ADME of a (13)C5-labeled anthocyanin in humans.

117 A systematic assessment of the ADME and PK properties of the new analogues led to drugl

118 onal screen for generating components of the ADME profile in a drug discovery process.

119 In addition, preliminary data on their ADME (absorption, distribution, metabolism, and excretio

120 This ADME profile met our selection criteria for once daily a

121 bution, metabolism, excretion, and toxicity (ADME-Tox) studies also suggested favorable drug-like pro

122 medicinal chemistry optimization, and unique ADME assays of our irreversible covalent drug discovery

123 In vitro studies to determine various ADME properties combined with calculated TPSA, clogP, an

124 e, in particular, exhibited optimal in vitro ADME and pharmacokinetics properties and dose-dependentl

125 In vitro ADME assays demonstrated that this novel chemotype posse

126 all molecule architecture on common in vitro ADME assays.

127 This model integrates existing in vitro ADME data, such as Caco-2 permeability (P(app)) and meta

128 ate human oral bioavailability from in vitro ADME data.

129 ntified inhibitor shows a favorable in vitro ADME profile as well as good oral bioavailability in mic

130 nds possesses a generally favorable in vitro ADME profile, along with good exposure levels in plasma

131 Boronate 30 displays a promising in vitro ADME profile, including plasma and mouse microsomal half

132 key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposure

133 cy criteria and displaying improved in vitro ADME profiles.

134 Using in vitro ADME profiling data, 9t was identified as possessing fav

135 tors which also exhibited favorable in vitro ADME properties (microsomal and hepatocyte stability, MD

136 Through the evaluation of opportune in vitro ADME properties, a potential candidate suitable for inha

137 3 and 38 from this series have good in vitro ADME properties, good oral bioavailability, and efficacy

138 The favorable potency, selectivity, in vitro ADME properties, in vivo PK, and dose-dependent inhibiti

139 positive attributes with respect to in vitro ADME properties.

140 within 8a, but retaining desirable in vitro ADME properties.

141 n combined with the high throughput in vitro ADME screening process, it has the potential to signific

142 o pharmacological, physicochemical, in vitro ADME, and in vivo pharmacokinetic studies in the rat and

143 The in vitro ADME-PK properties of the lead molecules were further op

144 wed potency and physicochemical and in vitro ADME-tox profiles comparable to propranolol.

145 Additionally, we present the in vitro ADME/DMPK parameters for a subset of the inhibitors as w

146 ted, has a profound influence on the in vivo ADME characteristics, and has considerable implications

147 Efforts to improve the in vitro and in vivo ADME properties of 4 while maintaining JAK1 selectivity

148 of our knowledge, this is the first in vivo ADME study of macrocyclic (acyloxy)alkoxy prodrugs, and

149 veloped, which enable users to predict which ADME relevant protein targets a novel compound is likely

150 ude the interactions of small molecules with ADME (absorption, distribution, metabolism and excretion